comparemela.com

Latest Breaking News On - Gary wong ka leung - Page 1 : comparemela.com

Hong Kong unveils next-gen drug for cancers associated with Epstein–Barr virus

Hong Kong unveils next-gen drug for cancers associated with Epstein–Barr virus Hong Kong unveils next-gen drug for cancers associated with Epstein–Barr virus 03 March 2021 | News HKBU has established a spin-off company named BP InnoMed Limited (BPI) to further develop this new anti-EBV drug and carry out clinical trials Source: PR Newswire A Hong Kong Baptist University-led (HKBU) research team has developed a novel drug which has the potential to become a next-generation treatment for cancers associated with Epstein–Barr virus (EBV). The peptide-linked drug, which is responsive to the acidic environment found in tumours, is the first known agent to have successfully targeted two viral proteins that are simultaneously produced by EBV. 

Hong-kong
Hong-lok
A-hong-kong
Gary-wong-ka-leung
Department-of-chemistry
Department-of-applied-biology
Hong-kong-polytechnic-university
Sun-yat-sen-university
Chemical-technology
Bp-innomed-limited
Baptist-university-led
Assistant-professor

HKBU develops dual-targeting drug for EBV-related cancers

Hong Kong Baptist University  A Hong Kong Baptist University-led (HKBU) research team has developed a novel drug which has thepotential to become a next-generation treatment for cancers associated with Epstein–Barr virus (EBV). The peptide-linked drug, which is responsive to the acidic environment found in tumours, is the first known agent to have successfully targeted two viral proteins that are simultaneously produced by EBV. It also offers a new strategy by increasing the uptake of anti-cancer drugs in tumour cells, thus allowing the application of lower drug dosages which helps reduce treatment side effects and health risks. The research results were published in the international academic journal

China
Hong-kong
Hong-lok
Gary-wong-ka-leung
Third-affiliated-hospital-at-sun-yat-sen-university
Hong-kong-polytechnic-university
Chemical-technology
Incu-bio-program-of-the-hong-kong-science
Bp-innomed-limited
Head-of-the-department-chemistry
Asian-fund-for-cancer-research
Technology-park

Novel dual-targeting drug could become a next-generation treatment for EBV-related cancers

Novel dual-targeting drug could become a next-generation treatment for EBV-related cancers
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.

China
Hong-kong
Hong-lok
Gary-wong-ka-leung
Emily-henderson
Hong-kong-polytechnic-university
Head-of-the-department-chemistry
Chemical-technology
Professor-of-the-department-applied-biology
Professor-of-the-department-chemistry
Hong-kong-baptist-university-led
Professor-gary-wong-ka-leung

HKBU develops dual-targeting drug for EBV-related cancers

HKBU develops dual-targeting drug for EBV-related cancers
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

China
Hong-kong
Kostenloser-wertpapierhandel
Hong-lok
Gary-wong-ka-leung
Third-affiliated-hospital-at-sun-yat-sen-university
Hong-kong-polytechnic-university
Chemical-technology
Incu-bio-program-of-the-hong-kong-science
Bp-innomed-limited
Asian-fund-for-cancer-research
Head-of-the-department-chemistry

HKBU develops dual-targeting drug for EBV-related cancers

HKBU develops dual-targeting drug for EBV-related cancers
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

China
Hong-kong
Hong-lok
Gary-wong-ka-leung
Third-affiliated-hospital-at-sun-yat-sen-university
Hong-kong-polytechnic-university
Hong-kong-baptist-university
Chemical-technology
Incu-bio-program-of-the-hong-kong-science
Bp-innomed-limited
Head-of-the-department-chemistry
Asian-fund-for-cancer-research
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.